The "EU Clinical Trial Regulation 536/2014: Compliance, Implementation & Best Practices Training (November 25, 2025)" training has been added to ResearchAndMarkets.com's offering.

This course covers the requirements for conducting Clinical Studies across the EU via the requirements of the EU Clinical Trial Regulation (for Drugs & Biologics).

The course also covers recent updates on EU-GCP associated with the new regulatory framework and highlights the new EU Pharmacovigilance Directive, as it relates to studies and helpful tips for working with European regulators. The seminar covers the impending changes coming with the EU Parliament's passage of the EU Clinical Trial Regulation, which will affect all trials conducted across the EU [new and ongoing].

This course also covers the various licensing methods (for Drugs, Biologics & Combination Products) by which applicants can file for product licenses (Marketing Authorizations) in one or multiple Member States [and EEA], as well as fully across all Member States of the European Union. This course specifically outlines and discusses the structure of the regulatory agencies at the EU level and across the specific Member States. Course content will explain which procedures are available for which products and then will follow the license processing steps for each pathway.

Learning Objectives

Attendees will leave the Course clearly understanding the requirements under the current Regulations. In addition, this course has been updated to provide participants with competitive insight into:

How the EU and individual countries within Europe Interact

• Which registration procedure to use
• How regulations affect product development strategies
• Understanding the concerns/issues of European Regulatory Personnel
• How to negotiate with the regulators
• Information necessary for effective submissions
• Strategies for streamlining the registration application process for faster approval
• The advantages and disadvantages of various registration procedures
• How to efficiently initiate trials first patient, first visit
• How to link the strategy of Country Selection to an ultimate EU registration pathway
• How to stay compliant What can make the difference in your data passing Regulatory scrutiny
• Related area-GCP and PV-reporting updates
• Impending Changes of the EU Clinical Trial Regulation and timing for Implementation

This live training Seminar includes the following for each registered attendee:

• A copy of the presentation slides by download
• A certificate of participation for attendee training records
• Q/A Session
• Free Handouts on EU Clinical Trial Regulation

Who Should Attend:

• Business Management: Gain insights into regulatory compliance and operational implications of EU CTR 536/2014 for strategic decision-making.
• Project Team Members: Understand trial planning, documentation, and cross-functional responsibilities to ensure smooth execution.
• Legal Team Members: Learn regulatory and legal requirements, risk mitigation, and compliance considerations for clinical trials.
• Clinical Operations Staff: Acquire practical knowledge on trial conduct, submission processes, and documentation under EU CTR.
• Quality Assurance, Monitors, CRAs: Understand inspection readiness, audit preparation, and quality control requirements.
• Regulatory Affairs Professionals: Master CTR application submissions, safety reporting, and regulatory alignment across member states.
• Investigators & Site Study Staff: Gain awareness of protocol compliance, reporting obligations, and essential document management.
• CROs, Consultants, and Insurers: Understand regulatory expectations, trial oversight, and risk management strategies for clinical trials.

Key Topics Covered:

Session 1: EU's New Regulation 535/2014 on Clinical Trials, 2022 (77 slides)

• Introduction - Foundation of Science-based Clinical Trials
• Clinical Trial Basics
• EU Regulation 536/2014, recently implemented
• Trial subjects' concerns / rights

Break

Session 2: ICH Q7 API CGMPs and QMS (81 slides)

• ICH Q7 API CGMP
• Additional CGMP considerations
• Required Records
• Methods Validation

Break

Session 3:Risk Management in EU New Drug Development (53 slides)

• ICH Q9
• Risk Management File - Narrative
• Hazards List, FTA, D-, P-, U-FME[C]A's
• Review / Report; Use

Session 4: Investigational Medicinal Products (IMPs) (22 slides)

• EU Medicinal Products Requirements
• IMPs

Session 5:EU Clinical Trials Application Process (36 slides)

• Application Process
• AMS, CMS
• Required documents.

Review

Q & A

Note: Times are approximate.

Speakers:

John E. Lincoln

Principal Consultant

J. E. Lincoln and Associates LLC

John E. Lincoln is principal of J. E. Lincoln and Associates LLC, a consulting company, with over 33 years' experience in U.S. FDA-regulated industries and 20 years as a full-time consultant. He has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan.

He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process/ product/ equipment including QMS and so+E6ftware validations, ISO 14971 product risk management files / reports, design control / design history files, and technical files. He's held positions in manufacturing engineering, QA, QAE, regulatory affairs, to the level of director and VP (R&D). In addition, Mr. Lincoln has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CGMP subjects. He is a graduate of UCLA.

For more information about this training visit https://www.researchandmarkets.com/r/zatqli

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028546563/en/